Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02134405
Recruitment Status : Unknown
Verified January 2016 by University of Malaya.
Recruitment status was:  Recruiting
First Posted : May 9, 2014
Last Update Posted : January 5, 2016
Sponsor:
Collaborators:
Zhejiang Provincial Hospital of TCM
Second Affiliated Hospital, School of Medicine, Zhejiang University
Information provided by (Responsible Party):
University of Malaya

Tracking Information
First Submitted Date  ICMJE May 7, 2014
First Posted Date  ICMJE May 9, 2014
Last Update Posted Date January 5, 2016
Study Start Date  ICMJE August 2014
Estimated Primary Completion Date June 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 8, 2014)
Dyspepsia symptoms [ Time Frame: 8 weeks ]
To assess the efficacy of Rebamipide in combination with Esomeprazole in the improvement of symptoms of Functional Dyspepsia in Asian patients compared to Esomeprazole alone.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 8, 2014)
quality of life [ Time Frame: 8 weeks ]
i. To assess the efficacy of Rebamipide in combination with Esomeprazole in the improvement of quality of life in Asian patients with Functional Dyspepsia compared to Esomeprazole alone
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: May 8, 2014)
  • Financial costs [ Time Frame: 12 weeks ]
    To assess the cost-effectiveness of Rebamipide in combination with Esomeprazole compared to Esomeprazole alone after 8, 12 weeks of treatment
  • Adverse events [ Time Frame: 12 weeks ]
    To assess the safety of Rebamipide in combination with Esomeprazole in adults with functional dyspepsia after 8 weeks of treatment
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia
Official Title  ICMJE Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study
Brief Summary This is a multi-Asian-centre randomised controlled trial of Rebamipide alone vs Rebamipide with Esomeprazole in the treatment of adult patients with Functional Dyspepsia. The hypothesis is that a combination therapy is superior to mono-therapy in the control of patients' symptoms and quality of life improvement.
Detailed Description

Primary Objective: To assess the efficacy of Rebamipide in combination with Esomeprazole in the improvement of symptoms of Functional Dyspepsia in Asian patients compared to Esomeprazole alone Secondary Objective: i. To assess the efficacy of Rebamipide in combination with Esomeprazole in the improvement of quality of life in Asian patients with Functional Dyspepsia compared to Esomeprazole alone ii. To assess the cost-effectiveness of Rebamipide in combination with Esomeprazole compared to Esomeprazole alone after 8, 12 weeks of treatment iii. To assess the safety of Rebamipide in combination with Esomeprazole in adults with functional dyspepsia after 8 weeks of treatment.

Trial Design Multi-national, randomised, double-blind, placebo-controlled study

Treatment Group:

  • Study Group: Rebamipide + Esomeprazole
  • Control Group: Rebamipide placebo + Esomeprazole Investigational Product (IP): Rebamipide 100 mg tablet Rebamipide placebo tablet Esomeprazole 20 mg tablet Dosage regimen: Administration route: PO Rebamipide 100 mg t.i.d Rebamipide placebo t.i.d Esomeprazole 20 mg o.d Target Population Male or female subjects aged from 18 years to less than 80 years with a diagnosed of Functional Dyspepsia (FD) Primary Endpoint: Change in Leeds Dyspepsia Questionnaire (LDQ) total score from baseline to 8 weeks of treatment Secondary Endpoints: 1. The change in Health-Related Quality of Life (EQ-5D) from baseline to 8 weeks of treatment 2. The cost effectiveness based on cost per QALY gained between the study group compared to the control group at 8, 12 weeks 3. The change in Leeds Dyspepsia Questionnaire (LDQ) total score and Health-Related Quality of Life (EQ-5D) from baseline to 12 weeks Inclusion Criteria: 1. Patients diagnosed with Functional Dyspepsia using Rome III diagnostic criteria 2. Age ≥ 18 years, < 80 years 3. Subject who has ability to provide written informed consent and willingness to comply with the requirement of the protocol 4. Able to communicate in English, Malay or Mandarin languages 5. Patients on prior dyspepsia treatment - after washout period of 1 week Exclusion Criteria: 1. Patients with known hypersensitivity to Rebamipide and/or Esomeprazole and any other component of these formulations.

    2. Pregnant, nursing, and childbearing potential women who is unwilling to effective contraception; for example, oral contraceptives, hormonal methods, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods (i.e., condom or occlusive cap with spermicidal foam/gel/film/cream/ suppository), male sterilization, and true abstinence 3. Presence of family history of GI malignancy or alarm features suggested malignancy - e.g. Unintentional weight loss (more than 10% of body weight in recent 6 months), GI bleeding 4. Patients consuming regular Aspirin or NSAIDs (except low-dose Aspirin at a dose of 325 mg/day or less for cardiovascular prophylaxis) 5. History of erosive esophagitis, peptic ulcer disease within 1 year prior to the screening 6. History of gastrointestinal (GI) malignancy, primary esophageal motility disorder, documented upper GI surgery 7. Patients with any hepatobiliary or pancreatic diseases 8. Patients with severe depression, anxiety, or other psychological disorder 9. Patients with any terminal disease 10. Presence of irritable bowel syndrome (Rome III criteria) or inflammatory bowel disease (IBD) 11. Necessary to have a continuous concomitant treatment with sucralfate, quinidine, warfarin, phenytoin, bisphosphonates, methotrexate, ketoconazole, fluconazole, itaconazole, diazepam, anti-cholinergics, H2RAs, PPIs (except study drug), prokinetics, and/or NSAIDs (except topical use of NSAIDs; in systemic NSAIDs ≤2 days/week) 12. Use of PPIs (except study drug), H2RAs, prokinetics, antibiotics (except topical use), misoprostol, or bismuth compounds within 1 week prior to the screening, and who were taking antibiotics used to eradicate Helicobacter pylori within 4 weeks prior to the screening 13. Unable to communicate in English, Malay, or Mandarin 14. Other conditions determined by the investigator to be inappropriate for this clinical study Duration of treatment: 8 weeks Number of subjects: Ninety-three patients per each group with 90% power at the 0.05 significance level were used. Considering 10% drop-out rate, total of 208 patients (104 patients per each group) will be enrolled in the study.

Total: 208 Study Group: 104 Control Group: 104 Anticipated Timelines: Duration of trial: 18 months Start of recruitment: March 2014 End of recruitment: August 2015 Last subject out: Oct 2015

Statistical Methodology:

Primary Endpoint Change in Leeds Dyspepsia Questionnaire (LDQ) total score from baseline to 8 weeks of treatment

Secondary Endpoint

  1. The change in Health-Related Quality of Life (EQ-5D) from baseline to 8 weeks of treatment
  2. The cost effectiveness based on cost per QALY gained between the study groups compared to the control group at 8, 12 weeks
  3. The change in Leeds Dyspepsia Questionnaire (LDQ) total score and Health-Related Quality of Life (EQ-5D) from baseline to 12 weeks

Summary statistics of the endpoints will be provided. Mean change will be evaluated by two sample t-test or Wilcoxon's rank sum test according to the normal distribution of analyzed variable.

Safety Endpoint

  1. Adverse events The number of cases of AEs and the proportion of patients who experienced AEs will be summarized by descriptive statistics (frequency and proportion) for each study group.
  2. Laboratory Test and Vital Signs All laboratory values and vital signs will be compared within study group and between study groups.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Dyspepsia
Intervention  ICMJE
  • Drug: Rebamipide
    Rebamipide 100mg tid
    Other Name: Mucosta
  • Drug: Placebo (for Esomeprazole)
    Sugar pill manufactured to mimic Esomeprazole
    Other Name: placebo
  • Drug: Esomeprazole
    Esomeprazole tablets 20mg o.d. for 8 weeks
    Other Name: Nexium
Study Arms  ICMJE
  • Experimental: Rebamipide and Esomeprazole
    Rebamipide tablets 100mg tid for 8 weeks Esomeprazole tablets 20mg od for 8 weeks
    Interventions:
    • Drug: Rebamipide
    • Drug: Esomeprazole
  • Active Comparator: Rebamipide and placebo
    Placebo drug with Rebamipide 100mg tid
    Interventions:
    • Drug: Rebamipide
    • Drug: Placebo (for Esomeprazole)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: May 8, 2014)
200
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2016
Estimated Primary Completion Date June 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients diagnosed with Functional Dyspepsia using Rome III diagnostic criteria
  2. Age ≥ 18 years, < 80 years
  3. Subject who has ability to provide written informed consent and willingness to comply with the requirement of the protocol
  4. Able to communicate in English, Malay or Mandarin languages
  5. Patients on prior dyspepsia treatment - after washout period of 1 week

Exclusion Criteria:

  1. Patients with known hypersensitivity to Rebamipide and/or Esomeprazole and any other component of these formulations.
  2. Pregnant, nursing, and childbearing potential women who is unwilling to effective contraception; for example, oral contraceptives, hormonal methods, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods (i.e., condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), male sterilization, and true abstinence
  3. Presence of family history of GI malignancy or alarm features suggested malignancy - e.g. Unintentional weight loss (≥ 10% of body weight in recent 6 months), GI bleeding
  4. Patients consuming regular Aspirin or NSAIDs (except low-dose Aspirin at a dose of 325 mg/day or less for cardiovascular prophylaxis)
  5. History of erosive esophagitis, peptic ulcer disease within 1 year prior to the screening
  6. History of gastrointestinal (GI) malignancy, primary esophageal motility disorder, documented upper GI surgery
  7. Patients with any hepatobiliary or pancreatic diseases
  8. Patients with severe depression, anxiety, or other psychological disorder
  9. Patients with any terminal disease
  10. Presence of irritable bowel syndrome (Rome III criteria) or inflammatory bowel disease (IBD)
  11. Necessary to have a continuous concomitant treatment with sucralfate, quinidine, warfarin, phenytoin, bisphosphonates, methotrexate, ketoconazole, fluconazole, itaconazole, diazepam, anti-cholinergics, H2RAs, PPIs (except study drug), prokinetics, and/or NSAIDs (except topical use of NSAIDs; in systemic NSAIDs ≤2 days/week)
  12. Use of PPIs (except study drug), H2RAs, prokinetics, antibiotics (except topical use), misoprostol, or bismuth compounds within 1 week prior to the screening, and who were taking antibiotics used to eradicate Helicobacter pylori within 4 weeks prior to the screening
  13. Unable to communicate in English, Malay, or Mandarin
  14. Other conditions determined by the investigator to be inappropriate for this clinical study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Malaysia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02134405
Other Study ID Numbers  ICMJE 037-OTC-1203i
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Malaya
Study Sponsor  ICMJE University of Malaya
Collaborators  ICMJE
  • Zhejiang Provincial Hospital of TCM
  • Second Affiliated Hospital, School of Medicine, Zhejiang University
Investigators  ICMJE
Principal Investigator: Sanjiv Mahadeva, MRCP, MD University Malaya
PRS Account University of Malaya
Verification Date January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP